Naltrexone for opioid use disorders a review of clinical effectiveness, cost-effectiveness, and guidelines
The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however, in Canada extended-release naltrexone is only available through the Health Canada's Special Access Programme or for research. Given the relative novelty of XR-NTX, its effectiveness compared with oral na...
Main Authors: | , |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
July 4, 2017, 2017
|
Edition: | Version 1.0 |
Series: | CADTH rapid response report: summary with critical appraisal
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references